Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

United Therapeutics (UTHR) Enterprise Value (2016 - 2025)

United Therapeutics (UTHR) has disclosed Enterprise Value for 17 consecutive years, with -$2.9 billion as the latest value for Q4 2025.

  • Quarterly Enterprise Value rose 10.61% to -$2.9 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$2.9 billion through Dec 2025, up 10.61% year-over-year, with the annual reading at -$2.9 billion for FY2025, 10.61% up from the prior year.
  • Enterprise Value hit -$2.9 billion in Q4 2025 for United Therapeutics, down from -$2.8 billion in the prior quarter.
  • In the past five years, Enterprise Value ranged from a high of -$1.7 billion in Q1 2021 to a low of -$3.3 billion in Q3 2024.
  • Historically, Enterprise Value has averaged -$2.7 billion across 5 years, with a median of -$2.8 billion in 2022.
  • Biggest five-year swings in Enterprise Value: tumbled 47.03% in 2022 and later grew 16.8% in 2025.
  • Year by year, Enterprise Value stood at -$1.9 billion in 2021, then plummeted by 47.03% to -$2.8 billion in 2022, then fell by 5.47% to -$3.0 billion in 2023, then dropped by 9.11% to -$3.3 billion in 2024, then rose by 10.61% to -$2.9 billion in 2025.
  • Business Quant data shows Enterprise Value for UTHR at -$2.9 billion in Q4 2025, -$2.8 billion in Q3 2025, and -$3.0 billion in Q2 2025.